Supplementary Appendix: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Published: 17 July 2024| Version 1 | DOI: 10.17632/nmhhzwb96h.1
Contributors:
Brett King, Maryanne Senna, Natasha Mesinkovska, Charles Lynde, Matthew Zirwas, Catherine Maari, Vimal Prajapati, Sheetal Sapra, Pawel Brzewski, Lawrence Osman, Sameh Hanna, Marni Wiseman, Colleen Hamilton, James CassellaDescription
Supplementary Appendix to: King B, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol 2024
Files
Categories
Dermatology
Funding
Sun Pharma (Japan)